MedTrace Logo

MDMA in Borderline Personality Disorder

NCT06683014 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-01-22

No results posted yet for this study

Summary

The purpose of this study is to test the effects of MDMA (3,4-methylenedioxymethamphetamine) on social cognition in adults with Borderline Personality Disorder.

Conditions

  • Borderline Personality Disorder

Interventions

DRUG

MDMA

Participants will receive one dose of open-label 3,4-methylenedioxymethamphetamine (MDMA).

Sponsors & Collaborators

  • Connecticut Mental Health Center

    collaborator UNKNOWN

  • Yale University

    lead OTHER

Principal Investigators

  • Sarah K Fineberg, MD, PhD · Yale University

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-05
Primary Completion
2026-09-30
Completion
2026-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06683014 on ClinicalTrials.gov